INTERNATIONAL PATENT: ALFASIGMA S.P.A. FILES APPLICATION FOR "BIOMARKERS FOR DETERMINING TREATMENT OF ULCERATIVE COLITIS WITH FILGOTINIB"

GENEVA, Feb. 9 -- ALFASIGMA S.P.A. (5, Via Ragazzi del '9940133 Bologna) filed a patent application (PCT/EP2025/072051) for "BIOMARKERS FOR DETERMINING TREATMENT OF ULCERATIVE COLITIS WITH FILGOTINIB" on Jul 31, 2025. With publication no. WO/2026/027669, the details related to the patent application was published on Feb 05, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): RANDALL, Matthew (Rue de la Grange Neuve 21036 Sullens)

Abstract: Filgotinib or a pharmaceutically acceptable salt thereof for use in a method of treating ulcerative colitis is provided, along with methods of deciding wheth...